Xu Li, Yang Mingyuan, Zhao Tiejun, Jin Hai, Xu Zhiyun, Li Ming, Chen Hezhong
From the Department of Cardiothoracic Surgery (LX, TZ, HJ, ZX, HC) ; and Department of Orthopaedics (MY, ML), Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China.
Medicine (Baltimore). 2014 Dec;93(27):e178. doi: 10.1097/MD.0000000000000178.
The purpose of this articles is to determine whether the cytochrome P450 2E1 (CYP2E1) Rsa I/Pst I gene polymorphism is correlated with respiratory system cancers. Respiratory system cancers included lung cancer, laryngeal cancer, nasopharyngeal cancer, and cancers of other respiratory organs, which are the most common malignant tumors worldwide; the significant relationship between CYP2E1 Rsa I/Pst I gene polymorphism and some respiratory system cancer have been reported, but results of some other studies are controversial. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to assess the association. PubMed, EMBASE, Cochrane Library Databases, China National Knowledge Infrastructure, and Wanfang Database (up to July 20, 2014) were searched for all case-control studies those mainly studied the relationship between CYP2E1 Rsa I/Pst I gene polymorphism and the susceptibility of respiratory system cancer. A total of 332 articles were collected, among which 34 studies that involved 7028 cases and 9822 controls fulfilled the inclusion criteria after being assessed by 2 reviewers. When stratified by cancer site, the C2/C2 polymorphism could increase the risk of nasopharyngeal cancer under the homozygote model (C2C2 vs C1C1: OR = 1.85, 95% CI = 1.20-2.85, P = 0.005) and recessive model (C2C2 vs C1C2/C1C1: OR = 1.89, 95% CI = 1.23-2.89, P = 0.003). Protection effect was found in lung cancer in heterozygote model (C1C2 vs C1C1: OR = 0.82, 95% CI = 0.74-0.91, P < 0.001), dominant model (C1C2/C2C2 vs C1C1: OR = 0.83, 95% CI = 0.76-0.90, P < 0.001), and allele contrast model (C2 vs C1: OR = 0.85, 95% CI = 0.73-1.00, P = 0.045). With regard to ethnicity subgroup analysis, there was significant association in Asian population in heterozygote model (C1C2 vs C1C1: OR = 0.85, 95% CI = 0.78-0.94, P = 0.001), dominant model (C1C2/C2C2 vs C1C1: OR = 0.88, 95% CI = 0.81-0.95, P = 0.001), and recessive model (C2C2 vs C1C2/C1C1: OR = 1.25, 95% CI = 1.01-1.53, P = 0.036). CYP2E1 Rsa I/Pst I gene polymorphism may reduce the risk of respiratory system cancer. Furthermore, significant association was also found in Asian populations.
本文的目的是确定细胞色素P450 2E1(CYP2E1)Rsa I/Pst I基因多态性是否与呼吸系统癌症相关。呼吸系统癌症包括肺癌、喉癌、鼻咽癌以及其他呼吸器官的癌症,这些是全球最常见的恶性肿瘤;已有报道称CYP2E1 Rsa I/Pst I基因多态性与某些呼吸系统癌症之间存在显著关联,但其他一些研究结果存在争议。计算合并比值比(OR)及95%置信区间(CI)以评估其关联性。检索了PubMed、EMBASE、Cochrane图书馆数据库、中国知网和万方数据库(截至2014年7月20日),查找所有主要研究CYP2E1 Rsa I/Pst I基因多态性与呼吸系统癌症易感性之间关系的病例对照研究。共收集到332篇文章,其中34项研究涉及7028例病例和9822例对照,经两名评审员评估后符合纳入标准。按癌症部位分层时,在纯合子模型(C2C2与C1C1:OR = 1.85,95% CI = 1.20 - 2.85,P = 0.005)和隐性模型(C2C2与C1C2/C1C1:OR = 1.89,95% CI = 1.23 - 2.89,P = 0.003)下,C2/C2多态性可增加鼻咽癌风险。在杂合子模型(C1C2与C1C1:OR = 0.82,95% CI = 0.74 - 0.91,P < 0.001)、显性模型(C1C2/C2C2与C1C1:OR = 0.83,95% CI = 0.76 - 0.90,P < 0.001)以及等位基因对比模型(C2与C1:OR = 0.85,95% CI = 0.73 - 1.00,P = 0.045)下,发现对肺癌有保护作用。关于种族亚组分析,在亚洲人群的杂合子模型(C1C2与C1C1:OR = 0.85,95% CI = 0.78 - 0.94,P = 0.001)、显性模型(C1C2/C2C2与C1C1:OR = 0.88,95% CI = 0.81 - 0.95,P = 0.001)和隐性模型(C2C2与C1C2/C1C1:OR = 1.25,95% CI = 1.01 - 1.53,P = 0.036)中存在显著关联。CYP2E1 Rsa I/Pst I基因多态性可能降低呼吸系统癌症风险。此外,在亚洲人群中也发现了显著关联。